Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
RESEARCH TOOLSreports
Holding MRVI?
Track your performance easily
MRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.52 - $11.56
Previous Close$7.41
Volume1.38M
Average Volume (3M)1.96M
Market Cap
$1.92B
Enterprise Value$2.19B
Total Cash (Recent Filing)$573.17M
Total Debt (Recent Filing)$554.76M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 07, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding252,237,419
10 Day Avg. Volume1,362,285
30 Day Avg. Volume1,959,159
Standard Deviation0.17
R-Squared0.00
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)4.41
Price to Sales (P/S)6.44
Price to Cash Flow (P/CF)25.70
P/FCF Ratio22.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.86
Enterprise Value/Gross Profit15.62
Enterprise Value/Ebitda72.77
Forecast
1Y Price Target
$11.11Price Target Upside49.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Maravai Lifesciences Holdings News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMaravai has delivered top-line beats for 3 consecutive quarters and remains on track for 2024 revenue targets.
Product Demand And GrowthGrowth was driven by higher demand for CleanCap analogs, GMP mRNA, and Glen Research products.
Strategic CollaborationsNew Hopkins collaboration on mRNA Innovation Center should further drive adoption over time.
Bears Say
EarningsEBITDA misses again on mix, startup costs & RD/collab investments.
Financial PerformanceBiologics Safety Testing fell ~5% year-over-year and ~18% quarter-over-quarter, to $14.9M, with the revenue shortfall attributed to disappointing China performance.
ProfitabilityAdjusted EBITDA was below the model and the 2024 adjusted EBITDA outlook was lowered, though 2024 revenue guidance was maintained.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MRVI FAQ
What was Maravai Lifesciences Holdings’s price range in the past 12 months?
Maravai Lifesciences Holdings lowest stock price was $4.52 and its highest was $11.55 in the past 12 months.
What is Maravai Lifesciences Holdings’s market cap?
Currently, no data Available
When is Maravai Lifesciences Holdings’s upcoming earnings report date?
Maravai Lifesciences Holdings’s upcoming earnings report date is Nov 07, 2024 which is in 4 days.
How were Maravai Lifesciences Holdings’s earnings last quarter?
Maravai Lifesciences Holdings released its earnings results on Aug 07, 2024. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.001.
Is Maravai Lifesciences Holdings overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings’s price is currently Undervalued.
Does Maravai Lifesciences Holdings pay dividends?
Maravai Lifesciences Holdings does not currently pay dividends.
What is Maravai Lifesciences Holdings’s EPS estimate?
Maravai Lifesciences Holdings’s EPS estimate is >-$0.01.
How many shares outstanding does Maravai Lifesciences Holdings have?
Maravai Lifesciences Holdings has 141,553,340 shares outstanding.
What happened to Maravai Lifesciences Holdings’s price movement after its last earnings report?
Maravai Lifesciences Holdings reported an EPS of $0 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -6.813%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings?
Among the largest hedge funds holding Maravai Lifesciences Holdings’s share is Gotham Asset Management LLC. It holds Maravai Lifesciences Holdings’s shares valued at 3M.
---
Maravai Lifesciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.11 (49.93% Upside)
$11.11 (49.93% Upside)
Blogger Sentiment
Neutral
MRVI Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 468.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.01%
12-Months-Change
Fundamentals
Return on Equity
-27.59%
Trailing 12-Months
Asset Growth
-36.07%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
---
MRVI Company Deck
---
MRVI Earnings Call
Q2 2024
0:00 / 0:00
---
MRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
---
MRVI Stock 12 Month Forecast
Average Price Target
$11.11
▲(49.93% Upside)
Technical Analysis
Best Analysts Covering MRVI
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-13.30%
reiterated a buy rating 11 days ago
Copying Conor McNamara's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -13.30% per trade.
---